NO20054070D0 - 4-[(2,4-diklor-5-metoksyfenyl)amino]-6-alkoksy-3-kinol inkarbonitriler for behandling av isjemisk skade. - Google Patents
4-[(2,4-diklor-5-metoksyfenyl)amino]-6-alkoksy-3-kinol inkarbonitriler for behandling av isjemisk skade.Info
- Publication number
- NO20054070D0 NO20054070D0 NO20054070A NO20054070A NO20054070D0 NO 20054070 D0 NO20054070 D0 NO 20054070D0 NO 20054070 A NO20054070 A NO 20054070A NO 20054070 A NO20054070 A NO 20054070A NO 20054070 D0 NO20054070 D0 NO 20054070D0
- Authority
- NO
- Norway
- Prior art keywords
- quinole
- carbonitriles
- methoxyphenyl
- dichloro
- alkoxy
- Prior art date
Links
- -1 2,4-Dichloro-5-methoxyphenyl Chemical group 0.000 title 1
- 125000004093 cyano group Chemical group *C#N 0.000 title 1
- 208000037906 ischaemic injury Diseases 0.000 title 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44931603P | 2003-02-21 | 2003-02-21 | |
| PCT/US2004/004904 WO2004075898A1 (en) | 2003-02-21 | 2004-02-19 | 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20054070D0 true NO20054070D0 (no) | 2005-09-01 |
| NO20054070L NO20054070L (no) | 2005-11-14 |
Family
ID=32927510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20054070A NO20054070L (no) | 2003-02-21 | 2005-09-01 | 4-[(2,4-diklor-5-metoksyfenyl)amino]-6-alkoksy-3-kinol inkarbonitriler for behandling av isjemisk skade. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20040229880A1 (no) |
| EP (1) | EP1594502A1 (no) |
| JP (1) | JP2006522023A (no) |
| KR (1) | KR20050102133A (no) |
| CN (1) | CN1750824A (no) |
| AR (1) | AR043253A1 (no) |
| AU (1) | AU2004216235A1 (no) |
| BR (1) | BRPI0407441A (no) |
| CA (1) | CA2516418A1 (no) |
| CO (1) | CO5640114A2 (no) |
| CR (1) | CR7931A (no) |
| EC (1) | ECSP055972A (no) |
| MX (1) | MXPA05008706A (no) |
| NO (1) | NO20054070L (no) |
| RU (1) | RU2005129333A (no) |
| TW (1) | TW200423938A (no) |
| UA (1) | UA80472C2 (no) |
| WO (1) | WO2004075898A1 (no) |
| ZA (1) | ZA200506621B (no) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004289243B2 (en) | 2003-11-06 | 2010-07-22 | Wyeth Llc | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
| PL1802581T3 (pl) * | 2004-10-22 | 2008-09-30 | Wyeth Corp | 4-[(2,4-dichloro-5-metoksyfenylo)amino]-6-alkoksy-7-etynylo-3-chinolinokarbonitryle do leczenia urazów niedokrwiennych |
| BRPI0613574A2 (pt) * | 2005-07-01 | 2016-11-16 | Wyeth Corp | forma cristalina isolada de um composto, método para preparar um composto, e, composição farmacêutica |
| RU2582610C2 (ru) * | 2010-07-30 | 2016-04-27 | Онкотерапи Сайенс, Инк. | Производные хинолина и содержащие их ингибиторы melk |
| CN103772392A (zh) * | 2012-10-23 | 2014-05-07 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| US10231965B2 (en) | 2014-02-20 | 2019-03-19 | Ignyta, Inc. | Molecules for administration to ROS1 mutant cancer cells |
| IN2014CH00840A (no) * | 2014-02-20 | 2015-09-18 | Apotex Inc | |
| US20160256457A1 (en) * | 2014-06-10 | 2016-09-08 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating or preventing acute vascular leak |
| CN107207471B (zh) | 2014-12-02 | 2020-06-26 | 伊尼塔公司 | 用于治疗神经母细胞瘤的组合 |
| WO2017029584A1 (en) * | 2015-08-19 | 2017-02-23 | Sun Pharmaceutical Industries Limited | Amorphous form of bosutinib |
| AU2016370846B2 (en) | 2015-12-18 | 2022-08-25 | Ignyta, Inc. | Combinations for the treatment of cancer |
| CN107814769B (zh) * | 2016-09-14 | 2021-05-07 | 正大天晴药业集团股份有限公司 | 一种博舒替尼的纯化方法 |
| JP7203083B2 (ja) | 2017-07-19 | 2023-01-12 | イグナイタ インコーポレイテッド | エントレクチニブを含む薬学的組成物 |
| EP3697390A1 (en) | 2017-10-17 | 2020-08-26 | Ignyta, Inc. | Pharmaceutical compositions and dosage forms |
| CN111646940B (zh) * | 2019-03-04 | 2024-01-30 | 鲁南制药集团股份有限公司 | 一种博舒替尼中间体的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6297258B1 (en) * | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| US6521618B2 (en) * | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| TWI275390B (en) * | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| AU2003279795A1 (en) * | 2002-10-04 | 2004-05-04 | Caritas St.Elisabeth's Medical Center Of Boston, Inc. | Inhibition of src for treatment of reperfusion injury related to revascularization |
-
2004
- 2004-02-18 TW TW093103901A patent/TW200423938A/zh unknown
- 2004-02-18 US US10/780,973 patent/US20040229880A1/en not_active Abandoned
- 2004-02-19 EP EP04712889A patent/EP1594502A1/en not_active Withdrawn
- 2004-02-19 JP JP2006503706A patent/JP2006522023A/ja not_active Withdrawn
- 2004-02-19 KR KR1020057015377A patent/KR20050102133A/ko not_active Application Discontinuation
- 2004-02-19 AU AU2004216235A patent/AU2004216235A1/en not_active Withdrawn
- 2004-02-19 CA CA002516418A patent/CA2516418A1/en not_active Abandoned
- 2004-02-19 RU RU2005129333/04A patent/RU2005129333A/ru not_active Application Discontinuation
- 2004-02-19 CN CNA2004800046743A patent/CN1750824A/zh active Pending
- 2004-02-19 MX MXPA05008706A patent/MXPA05008706A/es unknown
- 2004-02-19 BR BR0407441-6A patent/BRPI0407441A/pt not_active IP Right Cessation
- 2004-02-19 WO PCT/US2004/004904 patent/WO2004075898A1/en active Application Filing
- 2004-02-19 UA UAA200508924A patent/UA80472C2/uk unknown
- 2004-02-20 AR ARP040100546A patent/AR043253A1/es not_active Application Discontinuation
-
2005
- 2005-08-03 CR CR7931A patent/CR7931A/es not_active Application Discontinuation
- 2005-08-17 CO CO05081472A patent/CO5640114A2/es not_active Application Discontinuation
- 2005-08-18 ZA ZA200506621A patent/ZA200506621B/en unknown
- 2005-08-19 EC EC2005005972A patent/ECSP055972A/es unknown
- 2005-09-01 NO NO20054070A patent/NO20054070L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2516418A1 (en) | 2004-09-10 |
| US20040229880A1 (en) | 2004-11-18 |
| TW200423938A (en) | 2004-11-16 |
| EP1594502A1 (en) | 2005-11-16 |
| AR043253A1 (es) | 2005-07-20 |
| CN1750824A (zh) | 2006-03-22 |
| UA80472C2 (en) | 2007-09-25 |
| RU2005129333A (ru) | 2006-01-27 |
| WO2004075898A1 (en) | 2004-09-10 |
| KR20050102133A (ko) | 2005-10-25 |
| JP2006522023A (ja) | 2006-09-28 |
| CR7931A (es) | 2006-02-07 |
| CO5640114A2 (es) | 2006-05-31 |
| MXPA05008706A (es) | 2005-10-05 |
| ZA200506621B (en) | 2008-02-27 |
| NO20054070L (no) | 2005-11-14 |
| ECSP055972A (es) | 2006-01-16 |
| BRPI0407441A (pt) | 2006-01-31 |
| AU2004216235A1 (en) | 2004-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20054070D0 (no) | 4-[(2,4-diklor-5-metoksyfenyl)amino]-6-alkoksy-3-kinol inkarbonitriler for behandling av isjemisk skade. | |
| NL1026892A1 (nl) | ó1,8!Naftyridin-2-onen en verwante verbindingen voor de behandeling van schizofrenie. | |
| AP2005003350A0 (en) | 3-(3,5-dioxo-4,5-dihydro-3H-(1,2,4) triazin-2-yl)-benzamide derivatives as p2X7 -inhibitors for the treatment of inflammatory diseases. | |
| NO20081016L (no) | Nye 1-aryl-3-azabicyklo(3.1.0)heksaner, fremstilling og bruk for å behandle nevropsykiatriske lidelser | |
| DE602004024542D1 (de) | Untereinheit-impfstoff gegen das respiratorische synzytialvirus | |
| DE60236367D1 (de) | Echolöscher, der eine weitere reduktion des restechos sicherstellt | |
| ATE410430T1 (de) | 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose | |
| DK1697378T3 (da) | Indoler, 1H-indazoler, 1,2-benzisoxazoler og 1,2-benzisothiazoler og fremstilling og anvendelser deraf | |
| AP2006003514A0 (en) | Piperazine derivatives for the treatment of HIV infections. | |
| IL188483A0 (en) | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same | |
| DE602004024770D1 (de) | Substituierte 8-perfluoro-6,7,8,9-tetrahydropyrimido-(1,2a) pyrimidin-4-on derivate | |
| EG23318A (en) | Substituted aromatic amide derivative, intermediate thereof agrohorticultural insecticide containingthereof and method for the use thereof. | |
| NO20053348D0 (no) | Farmasoytisk sammensetning for behandling av virusangrep. | |
| HK1110025A1 (en) | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives the treatment of infertility | |
| NO20054034D0 (no) | Fremgangsmate for behandling av hypotyroidisme. | |
| IS7705A (is) | 4-(3,5-Dísýanófenoxý) pýrasól afleiður til notkunar sem bakritunarstillar við meðhöndlun á m.a. eyðniveirunni | |
| BR0116998B1 (pt) | dispositivo osteossintético. | |
| DE60315471D1 (de) | 2,5-disubstituierte 3-mercaptopentansaure | |
| ITTO20010694A0 (it) | Metodo di crittografia. | |
| EE05381B1 (et) | MeetodÁ2-(asendatudÁfenl)-2-hdroksetlkarbamaatideÁvalmistamiseks,ÁselleksÁvajalikudÁvahehendidÁningÁsaadudÁkarbamaatideÁpolmorfsedÁvormid | |
| IL182125A0 (en) | Optically active 4,4-di-substituted oxazolidine derivatives and processes for the preparation thereof | |
| ITRM20020308A1 (it) | Apparecchiatura per trattamenti terapeutici, e relativo metodo. | |
| ITMO20020368A1 (it) | Mezzi di finitura perfezionati. | |
| ITTO20030163A1 (it) | Dispositivo elaboratore per l'esecuzione di procedure fuzzy, relativo procedimento e prodotto informatico. | |
| IL160490A0 (en) | Systematical administration of some oxazolidinones, e.g. linezolid, for the treatment for ocular infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |